Abstract:
BACKGROUND:The South African national HIV plan recommends pre-exposure prophylaxis (PrEP) for transgender women, whose HIV prevalence estimates are as high as 25% in sub-Saharan Africa. The aim of this study was to explore PrEP awareness, uptake, and willingness, as well as associated barriers and facilitators, in order to inform PrEP implementation efforts with transgender women in South Africa. METHODS:Using a community-engaged, convergent parallel mixed methods design, trained local transgender women data collectors recruited 213 transgender women participants (aged >18 years, assigned male sex at birth, and identifying as a gender different from male), via network referral and word-of-mouth in Cape Town, East London, and Johannesburg. A subset of 36 transgender women also participated in qualitative in-depth interviews. Quantitative analyses included descriptive statistics and negative binomial regression models to assess correlates of PrEP willingness. Qualitative interviews were audio-recorded, transcribed verbatim, and coded. Thematic content analysis was used to identify key themes. Quantitative and qualitative data were integrated for interpretation. FINDINGS:Participants were recruited between June 1 and Nov 30, 2018. 57 (45%) of 127 HIV-negative participants were PrEP-aware and only 14 (11%) of 129 were currently taking PrEP. HIV-negative participants experiencing social (eg, violence, poverty) and interpersonal (eg, discrimination, low transgender women community connectedness) hardship reported PrEP awareness more frequently than HIV-negative transgender women who did not. Willingness to take PrEP was low, at 56 (55%) of 102, among HIV-negative participants who were not currently taking PrEP, and negatively associated with transgender women community connectedness (multivariable prevalence ratio 0·87; 95% CI 0·77-0·99). Barriers to PrEP included taking a daily pill, side-effects, and cost. Participants urged greater education and engagement of transgender women in PrEP implementation. INTERPRETATION:South Africa is poised to scale up PrEP services for transgender women. Dedicated transgender clinics are planned to provide comprehensive care, including PrEP, for transgender women. It is critical to ensure transgender women are aware of and have accurate information about PrEP, and that health-care sites are prepared to provide quality care for transgender women. FUNDING:Gilead Sciences.
journal_name
Lancet HIVjournal_title
The lancet. HIVauthors
Poteat T,Malik M,van der Merwe LLA,Cloete A,Adams D,Nonyane BAS,Wirtz ALdoi
10.1016/S2352-3018(20)30119-3subject
Has Abstractpub_date
2020-12-01 00:00:00pages
e825-e834issue
12eissn
2405-4704issn
2352-3018pii
S2352-3018(20)30119-3journal_volume
7pub_type
杂志文章相关文献
Lancet HIV文献大全abstract:BACKGROUND:Modest efficacy was reported for the HIV vaccine tested in the RV144 trial, which comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120). These vaccine components were adapted to express HIV-1 antigens from strains circulating in South Africa, and the adjuvant was changed to increase im...
journal_title:The lancet. HIV
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3018(18)30071-7
更新日期:2018-07-01 00:00:00
abstract:BACKGROUND:All recent treatment guidelines recommend integrase strand transfer inhibitors (INSTIs) as components of initial HIV therapy. Bictegravir, a novel, once-daily, unboosted INSTI, showed potent activity in a 10 day monotherapy study and has a high in-vitro resistance barrier. On the basis of these results, we d...
journal_title:The lancet. HIV
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3018(17)30016-4
更新日期:2017-04-01 00:00:00
abstract:BACKGROUND:Bictegravir co-formulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination is recommended for treatment of HIV-1-infection and might be better tolerated than other integrase inhibitor-based single-tablet regimens, but long-term outcomes data are not available. We assessed the efficacy...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3018(19)30077-3
更新日期:2019-06-01 00:00:00
abstract:BACKGROUND:The number of people on antiretroviral therapy (ART) requiring treatment monitoring in low-resource settings is rapidly increasing. Point-of-care (POC) testing for ART monitoring might alleviate burden on centralised laboratories and improve clinical outcomes, but its cost-effectiveness is unknown. METHODS:...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(20)30279-4
更新日期:2020-12-18 00:00:00
abstract::Progress in the development and introduction of paediatric formulations for key infectious diseases is poor in low-income and middle-income countries (LMICs). Although major steps have been made in the scale-up of antiretroviral medicines in LMICs, the development and deployment of formulations for infants and childre...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(18)30005-5
更新日期:2018-05-01 00:00:00
abstract:BACKGROUND:An intravaginal ring that releases the tenofovir prodrug, tenofovir disoproxil fumarate, provided 100% protection in macaques against simian HIV and was safe in a 14-day clinical trial in sexually abstinent women. We aimed to assess the safety and pharmacokinetics of this intravaginal ring over 90 days in se...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3018(19)30145-6
更新日期:2019-08-01 00:00:00
abstract:BACKGROUND:BMS-663068 is an oral prodrug of BMS-626529, an attachment inhibitor that binds to HIV-1 gp120, blocking viral attachment to host CD4 cells. AI438011 is an ongoing trial investigating the efficacy, safety, and dose-response of BMS-663068 in treatment-experienced, HIV-1-infected patients. Herein we present th...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3018(15)00177-0
更新日期:2015-10-01 00:00:00
abstract:BACKGROUND:ADVANCE compared the efficacy and safety of two antiretroviral first-line combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide), with a third regimen (efavirenz combined with emtricitabine and tenofovir disoproxil fumarate) previously recomm...
journal_title:The lancet. HIV
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3018(20)30241-1
更新日期:2020-10-01 00:00:00
abstract:BACKGROUND:Although lifelong combination antiretroviral therapy (ART) is recommended for all individuals with HIV, few data exist for pregnancy outcomes associated with ART initiation before conception. We assessed adverse pregnancy outcomes associated with ART initiated before conception compared with that of ART star...
journal_title:The lancet. HIV
pub_type: 杂志文章,meta分析,评审
doi:10.1016/S2352-3018(16)30195-3
更新日期:2017-01-01 00:00:00
abstract:BACKGROUND:Novel strategies are needed to increase retention in and uptake of prevention of mother-to-child HIV transmission (PMTCT) services in sub-Saharan Africa. We aimed to determine whether small, increasing cash payments, which were conditional on attendance at scheduled clinic visits and receipt of proposed serv...
journal_title:The lancet. HIV
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3018(15)00247-7
更新日期:2016-02-01 00:00:00
abstract:BACKGROUND:Measures of CD4 T-cell count and HIV-1 plasma viral load before antiretroviral therapy are proxies for virulence. Whether these proxies are changing over time has implications for prevention and treatment. The aim of this study was to investigate those trends. METHODS:Data were derived from the Concerted Ac...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(14)00002-2
更新日期:2014-12-01 00:00:00
abstract:BACKGROUND:Immune Reconstitution Inflammatory Syndrome (IRIS) is a common complication of antiretroviral therapy (ART) in HIV-infected patients. IRIS is associated with an increased risk of hospitalization and death. We ascertained whether CCR5 blockade using maraviroc reduces the risk of IRIS. METHODS:The CADIRIS stu...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(14)70027-X
更新日期:2014-11-01 00:00:00
abstract:BACKGROUND:In patients with HIV, immune reconstitution after antiretroviral therapy (ART) is often incomplete. We assessed the probability of patients reaching a CD4/CD8 ratio of 1 or more after the start of ART and its association with the onset of non-AIDS-defining events and death. METHODS:We did an analysis of the...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(15)00006-5
更新日期:2015-03-01 00:00:00
abstract:BACKGROUND:The HIV epidemic in the USA is a collection of diverse local microepidemics. We aimed to identify optimal combination implementation strategies of evidence-based interventions to reach 90% reduction of incidence in 10 years, in six US cities that comprise 24·1% of people living with HIV in the USA. METHODS:...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(20)30033-3
更新日期:2020-07-01 00:00:00
abstract:BACKGROUND:Standard approaches to estimation of losses in the HIV cascade of care are typically cross-sectional and do not include the population stages before linkage to clinical care. We used indiviual-level longitudinal cascade data, transition by transition, including population stages, both to identify the health-...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(16)30224-7
更新日期:2017-05-01 00:00:00
abstract:BACKGROUND:Pilot studies suggest that ritonavir-boosted darunavir could show high efficacy at doses below those currently approved. We investigated whether switch to 400 mg of darunavir boosted with 100 mg ritonavir once daily could show equivalent efficacy to continuation of ritonavir-boosted lopinavir (a protease inh...
journal_title:The lancet. HIV
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3018(19)30081-5
更新日期:2019-07-01 00:00:00
abstract::Despite considerable progress in paediatric HIV treatment and timely revision of global policies recommending the use of more effective and tolerable antiretroviral regimens, optimal antiretroviral formulations for infants, children, and adolescents remain limited. The Paediatric Antiretroviral Drug Optimization group...
journal_title:The lancet. HIV
pub_type: 杂志文章,评审
doi:10.1016/S2352-3018(19)30193-6
更新日期:2019-09-01 00:00:00
abstract:BACKGROUND:The burden of HIV in transgender women (transwomen) in Brazil remains unknown. We aimed to estimate HIV prevalence among transwomen in Rio de Janeiro and to identify predictors of newly diagnosed HIV infections. METHODS:We recruited transwomen from Rio de Janeiro, Brazil, by respondent-driven sampling. Elig...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(17)30015-2
更新日期:2017-04-01 00:00:00
abstract:BACKGROUND:Incarceration provides an opportunity for engagement in HIV care but is associated with poor HIV treatment outcomes after release. We aimed to assess post-release linkage to HIV care (LTC) and the effect of transitional case management services. METHODS:To create a retrospective cohort of all adults with HI...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(17)30209-6
更新日期:2018-02-01 00:00:00
abstract:BACKGROUND:Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against the most common NNRTI-resistant HIV-1 variants. We compared doravirine with ritonavir-boosted darunavir, when both were given with two...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3018(18)30021-3
更新日期:2018-05-01 00:00:00
abstract:BACKGROUND:In high HIV burden settings, maximising the coverage of prevention strategies is crucial to achieving epidemic control. However, little is known about the reach and effect of these strategies in some communities. METHODS:We did a cross-sectional community survey in the adjacent Greater Edendale and Vulindle...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(18)30104-8
更新日期:2018-08-01 00:00:00
abstract::The evaluation of immune-based approaches to achieve an antiretroviral therapy free remission of HIV infection requires proven efficacy through antiretroviral therapy interruption placebo-controlled trials. This approach is not without risk to participants and innovative trial designs need to be developed that minimis...
journal_title:The lancet. HIV
pub_type: 杂志文章,评审
doi:10.1016/S2352-3018(19)30082-7
更新日期:2019-05-01 00:00:00
abstract::South Africa intends to include dolutegravir in its first-line antiretroviral therapy (ART) regimen because of cost savings, the drug's high barrier to resistance, and efficacy. However, recent data from Botswana suggest potential teratogenicity of dolutegravir. WHO recommends that non-pregnant women of childbearing a...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(18)30249-2
更新日期:2018-12-01 00:00:00
abstract:BACKGROUND:Cabotegravir (GSK1265744) is an HIV-1 integrase strand transfer inhibitor with potent antiviral activity and a long half-life when administered by injection that prevented simian-HIV infection upon repeat intrarectal challenge in male macaques. We aimed to assess the safety, tolerability, and pharmacokinetic...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3018(17)30068-1
更新日期:2017-08-01 00:00:00
abstract:BACKGROUND:As access to antiretroviral therapy (ART) expands, increasing numbers of older patients will start treatment and need specialised long-term care. However, the effect of age in ART programmes in resource-constrained settings is poorly understood. The HIV epidemic is ageing rapidly and South Africa has one of ...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究
doi:10.1016/S2352-3018(15)00113-7
更新日期:2015-09-01 00:00:00
abstract:BACKGROUND:WHO-recommended second-line antiretroviral therapy (ART) of a pharmacologically enhanced (boosted) protease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs) might be compromised by resistance. Results of the 96 week SECOND-LINE randomised trial showed that NtRTI-sparing ART w...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3018(14)00061-7
更新日期:2015-02-01 00:00:00
abstract:BACKGROUND:HIV evolves rapidly and therefore infections with similar genetic sequences are likely linked by recent transmission events. Clusters of related infections can represent subpopulations with high rates of transmission. We describe the implementation of an automated near real-time system to monitor and charact...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(16)00046-1
更新日期:2016-05-01 00:00:00
abstract:BACKGROUND:The HIV epidemic in the population of Nairobi as a whole is in decline, but a concentrated sub-epidemic persists in key populations. We aimed to identify an optimal portfolio of interventions to reduce HIV incidence for a given budget and to identify the circumstances in which pre-exposure prophylaxis (PrEP)...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(17)30021-8
更新日期:2017-05-01 00:00:00
abstract:BACKGROUND:Universal antiretroviral therapy (ART), as per the 2015 WHO recommendations, might reduce population HIV incidence. We investigated the effect of universal test and treat on HIV acquisition at population level in a high prevalence rural region of South Africa. METHODS:We did a phase 4, open-label, cluster r...
journal_title:The lancet. HIV
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3018(17)30205-9
更新日期:2018-03-01 00:00:00
abstract:BACKGROUND:As HIV incidence and mortality continue to increase in eastern Europe and central Asia, particularly among people who inject drugs (PWID), it is crucial to effectively scale-up opioid agonist therapy (OAT), such as methadone or buprenorphine maintenance therapy, to optimise HIV outcomes. With low OAT coverag...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(19)30373-X
更新日期:2020-02-01 00:00:00